Drug intelligence / Profile preview

FB-2710

Development stage: Preclinical
Lead developer: Filament BioSolutions
Administration: Oral

Overview

FB-2710 is an orally administered, glutamine-based medical food candidate being developed by Filament BioSolutions for the management of radiation-induced oral mucositis in patients with cancer receiving radiotherapy and/or chemoradiation. It is formulated to optimize the bioavailability and cellular uptake of glutamine, a critical nutrient and energy substrate for rapidly dividing cells, with the goal of supporting mucosal integrity and promoting healing of the oral epithelium during cytotoxic therapy.[1][7] FB-2710 is part of a portfolio of evidence-based oncology co-therapies and medical foods being advanced in partnership with Ajinomoto.[1][7]

Beyond the preview

Go deeper on FB-2710.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB-2710.

Explore the full profile